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Abstract  51 
Background : COVID-19 can manifest as a viral induced hyperinflammation with multi-organ 52 
involvement. Such patients often experience rapid deterioration and need for mechanical 53 
ventilation. Currently, no prospectively validated biomarker of impending respiratory failure is 54 
available. 55 
Objective : We aimed to identify and prospectively validate biomarkers that allow the 56 
identification of patients in need of impending mechanical ventilation. 57 
Methods : Patients with COVID-19 hospitalized from February 29th to April 09th, 2020 were 58 
analyzed for baseline clinical and laboratory findings at admission and during the disease. 59 
Data from 89 evaluable patients were available for the purpose of analysis comprising an 60 
initial evaluation cohort (n=40) followed by a temporally separated validation cohort (n=49). 61 
Results : We identified markers of inflammation, LDH and creatinine as most predictive 62 
variables of respiratory failure in the evaluation cohort. Maximal interleukin-6 (IL-6) levels 63 
before intubation showed the strongest association with the need of mechanical ventilation 64 
followed by maximal CRP. Respective AUC values for IL-6 and CRP in the evaluation cohort 65 
were 0.97 and 0.86 and similar in the validation cohort 0.90 and 0.83. The calculated optimal 66 
cutoff values in the course of disease from the evaluation cohort (IL-6> 80 pg/ml and CRP> 67 
97 mg/l) both correctly classified 80% of patients in the validation cohort regarding their risk 68 
of respiratory failure.  69 
Conclusion : Maximal levels of IL-6 followed by CRP were highly predictive of the need for 70 
mechanical ventilation. This suggests the possibility of using IL-6 or CRP levels to guide 71 
escalation of treatment in patients with COVID-19 related hyperinflammatory syndrome. 72 
  73 
Clinical Implications: IL-6 followed by CRP strongly predicted patients at risk of respiratory 74 
deterioration and might be pivotal for risk-adapted escalation of treatment. 75 
Capsule summary:  We studied laboratory parameters as predictors of impending 76 
respiratory failure in COVID-19. Maximum levels of interleukin-6 over the course of disease, 77 
followed by CRP, were the best predictors of respiratory failure in two separate cohorts. 78 
Key words: Interleukin-6, IL-6, CRP, COVID-19, respiratory failure, mechanical ventilation, 79 
prediction, hyperinflammation  80 
Abbreviations: COVID-19: Coronavirus Disease 2019; SARS-CoV-2: Severe Acute 81 
Respiratory Syndrome coronavirus 2; SARS: severe acute respiratory syndrome; H7N9: 82 
avian-origin influenza; H1N1: influenza A; BAL: Bronchoalveolar lavage; ROC: Receiver 83 
operating characteristic; AUC: Area under the curve; CI: Confidence interval; BMI: Body 84 
mass index; CT: Computed Tomography; CRP: C-Reactive Protein; WBC: White blood cell 85 
count; LDH: Lactate Dehydrogenase; PCT: Procalcitonin; IL6: Interleukin-6; qSOFA score: 86 
quick sequential organ failure assessment score - predicts mortality in sepsis; CURB-65 87 
score: predicts mortality in community-acquired pneumonia; MuLBSTA score: predicts 88 
mortality in patients with viral pneumonia; q-values represent the Benjamini-Hochberg 89 
adjusted p-values 90 
 91 
  92 
Introduction 93 
The pandemic Coronavirus-disease 19 (COVID-19) is characterized by a highly variable 94 
course. While most patients experience only mild symptoms, a relevant proportion develops 95 
severe disease progression up to respiratory failure. Interestingly, many patients do not show 96 
signs of respiratory distress, despite severe hypoxemia in blood gas analysis 1. About 5% of 97 
patients require intensive care including mechanical ventilation 2, 3. 98 
Recently published large retrospective analyses provide a detailed characterization of 99 
COVID-19 and identify variables associated with disease severity and high mortality 4, 5. One 100 
of the largest studies so far shows that age, quick sequential organ failure assessment score 101 
(qSOFA score) and D-Dimer correlate with in-hospital death in a multivariate analysis 2. 102 
Another group showed a correlation of obesity and increased inflammatory markers in the 103 
blood with respiratory failure 6.  104 
In many aspects, severe COVID-19 may be regarded as a viral induced hyperinflammatory 105 
condition with multi-organ involvement due to a cytokine cascade 7. Of these various 106 
cytokines, the presence of raised circulating levels of interleukin-6 (IL-6) appears to be key 107 
and is closely connected to disease severity not only in COVID-19 8 but also in avian-origin 108 
H7N9 influenza infections 9 and the common seasonal H1N1 influenza A 10.  109 
While these studies identify the correlation of parameters with disease severity, prospective 110 
factors predicting impending deterioration of patients are not yet established. The broad 111 
spectrum of the disease courses and silent hypoxia make identification of patients at risk 112 
difficult. We aimed to identify variables that allow the prediction of COVID-19 patients with a 113 
high risk of respiratory failure. 114 
 115 
  116 
Methods 117 
Patients and study design 118 
All patients with PCR proven COVID-19 hospitalized at our institution from February 29th to 119 
April 09th, 2020 (n=115) were screened and analyzed for baseline clinical and laboratory 120 
findings. In total, 26 patients were excluded from the study and the depicted cohort consisted 121 
of 89 patients (Table 1). Patients with palliative treatment (n=3) or hospitalization due to other 122 
medical reasons and nosocomial Sars-CoV2-infection on the ward (n=13) were excluded 123 
from this study. Additionally, patients already mechanically ventilated at admission (n=8) and 124 
those receiving anti-IL-6 antibody treatment (n=2) were excluded (Figure 1). 125 
Of the 89 evaluable patients, 40 were part of an initial evaluation cohort hospitalized from 126 
February 29th to March 27th, 2020 (Supplementary Table E1). This cohort was used to 127 
identify predictive markers of respiratory failure.  128 
Following an interim analysis of the initial evaluation cohort11, we performed a power analysis 129 
to estimate the number of patients needed to validate our findings. Assuming the need of 130 
mechanical ventilation to be 20% in the validation cohort and the risks for mechanical 131 
ventilation to be 70% and 20% in the high-risk and the low-risk group, respectively, the total 132 
sample size for a two-sided test was determined to be 40. We defined an additional safety 133 
margin of 10%. This subsequent validation cohort consisted of patients hospitalized from 134 
March 27th to April 09th, 2020 (n=49) (Supplementary Table E2). Follow up for all patients 135 
was complete through April 12th, 2020. A comparison of both cohorts is shown in 136 
Supplementary Table E3.  137 
Use of compassionate medication was low in the study cohort before mechanical ventilation 138 
(5 patients received lopinavir/ritonavir, 8 patients received hydroxychloroquine).  139 
Decision on endotracheal intubation was made following internationally accepted 140 
recommendations (PaO2/FiO2 <150mmHg or <200mmHg in case of anticipated difficult 141 
airway) 12. 142 
Patients are part of the COVID-19 Registry of the Ludwig-Maximilian-University Hospital 143 
Munich (CORKUM). Patient data were anonymized for analysis and the study was approved 144 
by the local ethics committee (Ethics committee of the LMU Munich, No: 20-245). 145 
IL-6 and CRP measures 146 
The fully automated Elecsys® system on a cobas e801 platform (Roche Diagnostics, 147 
Switzerland) was used to measure single levels of IL-6, as described previously 13, 14. The 148 
Elecsys® IL-6 immunoassay has been standardized against the NIBSC 1st IS 89/548 149 
Standard. CRP values were measured on a cobas c702 platform using the Tina-quant® C-150 
Reactive Protein assay (Roche Diagnostics, Switzerland). 151 
Statistical analysis 152 
All variables with less than 50% of missing data in the initial cohort were tested for the 153 
association with respiratory failure. Categorical variables were tested with the χ2 test, and 154 
numerical variables with the Mann-Whitney U test. When appropriate, a paired test was 155 
performed. All tests were two-sided. The p-values were adjusted for multiple testing with the 156 
Benjamini-Hochberg-method to avoid inflating the alpha error. An adjusted p-value (q-value) 157 
of ≤0.05 was considered significant. We constructed receiver operating characteristic (ROC) 158 
curves and calculated the area under the curve (AUC) to compare the predictive ability of 159 
continuous variables. The AUC can be interpreted as the probability that the predictor’s value 160 
for a randomly chosen patient requiring intubation will be higher than its value for a randomly 161 
chosen patient not requiring intubation. The optimal cut off was defined as the one 162 
maximizing the Youden’s Index 15. Statistical analyses were performed using the R software 163 
package (version 3.6.2). Figures were drawn using Graphpad Prism® (Version 6.0). 164 
 165 
  166 
Results 167 
Initial identification of IL-6 and CRP as strongest  predictors of respiratory failure 168 
To initially evaluate predictors of respiratory failure, 40 patients with confirmed COVID-19 169 
were recruited from February 29th to March 27th, 2020 and served as an evaluation cohort 170 
(Figure 1). Thirteen (32.5%) patients deteriorated during hospitalization and required 171 
mechanical ventilation. The time from hospital admission to intubation varied from less than 172 
two hours to 9 days (median 2 days). Patients requiring mechanical ventilation did not differ 173 
in age, comorbidities, radiological findings, respiratory rate or qSofa score (Supplementary 174 
Table E1).  175 
Heart rate, markers of inflammation, LDH and creatinine at admission were significantly 176 
associated with respiratory failure (Supplementary Table E1). Elevated IL-6 showed the 177 
strongest association with the need for mechanical ventilation (Figure 2A, p=1.2x10-5). 178 
In addition to values at first assessment, follow-up data were available for laboratory 179 
variables. These follow-up data were used to test if there are critical laboratory values that 180 
are associated with respiratory failure once they have been reached during disease course. 181 
For each patient, we assessed the maximum level of each parameter during disease (for 182 
patients requiring ventilation, only values before intubation were used). The maximal values 183 
were correlated with respiratory failure (Table 2). Maximal IL-6 levels predicted respiratory 184 
failure with highest accuracy (Figure 2, AUC=0.97, CI [0.93, 1.0]), followed by CRP (Figure 3 185 
AUC=0.86, CI [0.74, 0.98]) and creatinine (AUC=0.85, CI [0.74, 0.97]). The optimal cutoff for 186 
maximal IL-6 was 80 pg/ml. After reaching an IL-6 value of 80 pg/ml, the median time to 187 
mechanical ventilation was 1.5 days (range 0–4 days). The optimal cutoff for maximal CRP 188 
was 97 mg/l, with the median time to mechanical ventilation of 0 days after reaching the 189 
cutoff (range 0–4 days).  190 
Prospective validation of calculated cutoffs for IL -6 and CRP 191 
A cohort of 40 patients was estimated to have an adequate power to validate our findings 192 
(see Methods). The validation cohort prospectively recruited 49 patients from March 27th to 193 
April 09th, 2020, of which 19 (39%) required mechanical ventilation. As in the initial cohort, 194 
creatinine, LDH, and several markers of inflammation were significantly elevated in patients 195 
requiring intubation (Table 2 and Supplementary Table E2). Again, IL-6 at assessment was 196 
strongly associated with respiratory failure (Figure 2B), and maximal IL-6 was the best 197 
predictor of future respiratory failure among all parameters (Figure 2D, AUC 0.90, CI [0.81, 198 
0.98], Table 2). CRP values at initial assessment were significantly associated with 199 
respiratory failure (Figure 2F and Figure 3 AUC=0.86, CI [0.75, 0.96]). Follow-up values of 200 
CRP during the disease course did not improve the prediction of respiratory failure in the 201 
validation cohort (Table 2, AUC=0.83, CI [0.72, 0.95]). 202 
To validate our findings from the initial cohort, we analyzed the number of patients correctly 203 
classified regarding their need of mechanical respiratory support by the determined cutoffs of 204 
IL-6 and CRP at presentation and in the course of disease (Table 3). At presentation, IL-6 205 
>35 pg/ml as well as CRP >32.5 mg/l showed high sensitivity to detect patients at risk for 206 
respiratory failure (84% and 95%) with moderate specificity (63% for both parameters). 207 
Measuring IL-6 and CRP values in the course of disease (cutoffs 80 pg/ml and 97 mg/l) 208 
increased the specificity for both parameters (83% and 77%) accompanied with a decrease 209 
in sensitivity (74% vs. 84%). In detail, nineteen (39%) patients exceeded the calculated 210 
maximal IL-6 cutoff (>80 pg/ml) in the validation cohort, compared to 23 (47%) patients 211 
exceeding the CRP cutoff (>97mg/l). Of these patients, 74% and 70% were correctly 212 
classified by IL-6 and CRP, respectively, as being at risk for respiratory failure (positive 213 
predictive value). Of the 30 patients with values below the IL-6 cutoff, 83% did not require 214 
mechanical ventilation, while this was the case for 88% of the 26 patients remaining below 215 
the CRP cutoff of 97 mg/l (negative predictive value). In total, the calculated cutoffs for 216 
maximal IL-6 and CRP both correctly classified 80% of patients regarding their risk of 217 
respiratory failure (Table 3), while values at assessment show poorer predictor properties 218 
owing to the moderate specificity (correct classification of 71% for IL-6 and 76% for CRP)  219 
Taken together, while both values have a strong sensitivity at assessment, specificity is 220 
gained when examining values in the course of disease. The risk ratios for the cutoffs of IL-6 221 
and CRP were 4.4 and 6.0 in the validation cohort, with corresponding p-values of 0.00022 222 
and 0.00011. The optimal cut point in the validation cohort was slightly lower for IL-6 (60 223 
pg/ml) and identical for CRP (97 mg/l). 224 
Predictive values of the combined cohort 225 
To further evaluate positive and negative predictive values (PPV/NPV) of IL-6 and CRP we 226 
combined the two cohorts (Table 1). We calculated predictive values across the range of all 227 
possible cutoffs. The PPV of CRP was consistently lower compared to IL-6 in the overall 228 
study cohort (Figure 4). In other words, increased CRP misclassified more patients as being 229 
at risk for respiratory failure than IL-6. However, the predictive values strongly depend on the 230 
selected cutoff (Figure 4). For cutoffs <50 pg/ml for IL-6 and <40 mg/l for CRP (dotted line), 231 
the risk of intubation for patients with sub-threshold levels is roughly zero, while patients with 232 
levels above these values show a dramatic increase in the risk of respiratory failure. The risk 233 
for respiratory failure in patients with IL-6 levels exceeding 210 pg/ml was 100% (dashed 234 
line). The NPV of IL-6 and CRP parameters was comparable. In the combined cohort, the 235 
optimal threshold value (maximal Youden index15) is highest at 65 pg/ml for IL-6 and for CRP 236 
at 97 mg/l (corresponding risk ratio of 18.1 and 6.9). 237 
Furthermore, we analyzed the time lag from reaching the cutoff values to intubation in the 238 
combined cohort. Patients reached the cutoff of IL-6 (>65 ng/ml) and CRP (>97 mg/l) at a 239 
median of 23.2 and 15.7 hours before intubation, resulting in a significant time difference 240 
between the two values of 7.5 hours in favor for IL-6 (Figure 5; p=0.014).  241 
 242 
  243 
Discussion 244 
Our study in hospitalized patients with COVID-19 has provided three key findings: First, 245 
circulating levels of IL-6 as well as CRP were highly predictive of the need for invasive 246 
ventilation, with corresponding AUC values of 0.97 and 0.90 for IL-6 and 0.86 and 0.83 for 247 
CRP in the first and the second cohorts, respectively. Secondly, we defined cutoffs for IL-6 248 
(at presentation >35 pg/ml; maximal value >80 pg/ml) and CRP (at presentation >32.5 mg/l; 249 
maximal value >97 mg/l) in the evaluation cohort. Cutoff values at assessment correctly 250 
classified 71% (for IL-6) and 76% (for CRP) of patients in the validation cohort with a further 251 
increase when measuring maximal values in the course of disease (80% for both 252 
parameters). Thirdly, elevated IL-6 levels in the course of disease predicted respiratory 253 
failure significantly earlier than CRP (23.2 vs. 15.7 hours). Therefore, IL-6 and CRP are 254 
useful markers that predict impending respiratory failure with high accuracy and can help 255 
physicians correctly allocate patients who might benefit from early treatment escalation, for 256 
example using anti-cytokine strategies. We believe that having these data reproduced across 257 
the two separate cohorts enhances the strength of our conclusions. It is important to note 258 
that the commercial diagnostic IL-6 assay used in our study allows the measurement of Il-6 259 
in a comparable time scale as CRP. Since it uses the broadly available Cobas platform it can 260 
be implemented in most laboratories. 261 
Our study also has several limitations. It is still unclear whether elevated inflammatory 262 
markers merely represent an epiphenomenon or a causal pathogenic element of severe 263 
COVID-19 16. It is likely that elevated IL-6 reflects the cytokine mediated hyperinflammatory 264 
state as evidenced by the similarly predictive values for CRP. Further, even though IL-6 and 265 
CRP levels are significantly elevated in patients requiring ventilation, they are relatively low 266 
compared to levels observed in patients with septic shock 17. However, earlier studies in 267 
severe acute respiratory syndrome (SARS) or H7N9 influenza patients show that 268 
inflammatory cytokines are highly expressed in lung tissues. Autopsy reports from SARS 269 
patients showed a high amount of inflammatory cytokines in cells expressing angiotensin-270 
converting enzyme 2 18, the functional receptor for SARS-CoV and in even higher affinity for 271 
SARS-CoV2 19. Bronchoalveolar lavage (BAL) in H7N9 influenza patients showed 103 times 272 
higher concentrations of different cytokines including IL-6 compared to plasma levels, hinting 273 
towards a massively increased local concentration of inflammatory cytokines in the diseased 274 
lung 9. Recent preprints provide detailed single cell RNA-sequencing data from immune cells 275 
in peripheral blood as well as BAL from COVID-19 patients. The authors report that 276 
peripheral monocytes did not substantially express proinflammatory cytokines 20, while there 277 
was high expression in monocyte derived macrophages in BAL 21. Taken together, these 278 
data possibly suggest that circulating levels of IL-6 might be a putative surrogate for the 279 
burden of lung tissue damage and provide a “window” into the lung 9.  280 
IL-6 and CRP have been associated with severity of COVID-19 (in most cases defined by the 281 
Chinese National Health Commission) and mortality before 22-24. However, to our knowledge 282 
our study is the first to demonstrate a prospective prediction of the end point “mechanical 283 
ventilation”, which is of high clinical relevance not only for patient treatment but also for 284 
resource planning. Very recent publications provide additional data that strengthen the role of 285 
IL-6 and CRP in COVID-19 as predictive markers 22, 23. Unfortunately, these studies did not 286 
include a prospective validation cohort and sometimes did not mention analysis platforms 22. 287 
A further difference between our and other studies is the dramatic discrepancy in mortality of 288 
severely diseased patients. We are not able to analyze mortality as an end point because 289 
only two patients had died until April 12th. This number has only increased by one until May 290 
6th (overall mortality 3.4%). While still some patients are in critical condition and the mortality 291 
rate in our cohort is likely to increase in the next weeks it will be significantly below those 292 
reported. We can only speculate about the reasons for this huge difference but argue that 293 
overwhelmed hospitals and patient selection might have contributed to the increased 294 
mortality observed in other studies. As we did not perform sequential CT-scans after 24-48 295 
hours in our patients due to radiation hygiene, we are not able to precisely calculate severity 296 
of COVID-19 according the Chinese National Health Commission classification to compare 297 
our patient cohort to the cohorts of the mentioned studies. However, our validation cohort at 298 
least exists of 63% of severe patients due to the available parameters (2% with mild and 299 
35% with moderate symptoms), which exceeds the recently published cohorts 22, 23. 300 
Since the start of the pandemic, hundreds of research articles on COVID-19 have been 301 
published 25. To our knowledge, we report the first predictive marker for respiratory failure 302 
that was prospectively validated in an independent cohort. Although our sample sizes were 303 
small, the large difference in risk for respiratory failure between the high-risk and the low-risk 304 
group made it possible to successfully validate our findings. Interestingly, a study of 134 305 
patients with avian-origin H7N9 influenza in 2013 also showed a strong correlation of IL-6 306 
and disease severity. In analogy to our findings, this study reports that IL-6 plasma levels 307 
>80 pg/ml were found in all patients with lethal outcome compared to only 8.3% in surviving 308 
patients 9. The combined cohort (n=89) produced an only slightly lower cutoff for IL-6 (65 309 
pg/ml) while the cutoff for CRP levels remained the same at 97 mg/l when calculated from 310 
the combined cohort. However, even the combined sample size is probably too small to 311 
determine an optimal cutoff value. Furthermore, the acceptable proportion of falsely identified 312 
low-risk patients, and therefore the set threshold, is largely dictated by the availability of 313 
health care resources. Future prospective studies with larger sample sizes are needed to 314 
formally address this issue. We want to stress that IL-6 and CRP should be used as a 315 
predictor not an indication for invasive respiratory support, as mechanical ventilation per se 316 
has several unintended adverse consequences and may support inflammation of distal 317 
airways in COVID-19 patients. 318 
Immunologically, CRP and IL-6 are closely intertwined. IL-6 is known to induce gene 319 
expression and release of CRP from the liver 26, 27 and also from immune cells 28. A functional 320 
connection has been shown in different trials using IL-6 inhibition, in which CRP-levels 321 
rapidly normalized after blocking IL-6 29. In analogy, we found that IL-6 levels predicted 322 
respiratory failure significantly earlier than CRP-levels, which is essential for a predictive 323 
marker. While inhibition of inflammatory pathways represents a promising approach to treat 324 
hyperinflammatory COVID-19 patients, inhibition of IL-6 could be detrimental in the immune 325 
response to virus-induced pneumonias 30, 31. Thus, our study does not facilitate any 326 
recommendations for or against IL-6 inhibition. Ongoing randomized controlled clinical trials 327 
of IL-6-antibodies in the treatment of COVID-19 will shed light on this question (e.g. 328 
NCT04320615 and NCT04331795). More importantly, in times of missing established 329 
therapeutic options, best supportive care is essential 32.  330 
In summary, we were able to validate our finding that IL-6 and CRP levels serve as strong 331 
predictors of patients in need of ventilator support. In the current situation with overwhelmed 332 
intensive care units and overcrowded emergency rooms, correct identification of patients in 333 
need of intensive care is crucial. Assessing these parameters to identify patients at risk of 334 
respiratory failure at an early stage might be helpful for triage planning and timely allocation 335 
of critically ill patients as well as a guide to escalation of treatment strategies in COVID-19 336 
patients. 337 
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Tables 448 
Table 1: Combined Cohort 449 
Variable  Evaluable  Median 
(range) / n (%) 
Mechanical ventilation  p-value  q-value  
No (n = 57) Yes (n = 32) 
Baseline Characteristics *  
Age (years) 89 61 (18 - 84) 58 (18 - 84) 65 (45 - 81) 0.031 0.067 
Respiratory rate (/min) 74 18 (11 - 40) 17 (13 - 39) 25 (11 – 40) 0.0024 0.0073 
Heart rate (/min) 66 86 (54 - 130) 85 (54 - 
130) 
89 (64 - 112) 0.32 0.47 




27.6 (18.3 – 
45.7) 
0.074 0.15 
Male gender 89 62 (70) 33 (58) 29 (91) 0.0029 0.0073 
Any comorbidities 87 70 (80) 43 (77) 27 (87) 0.38 0.53 
Hypertension 86 45 (52) 25 (45) 20 (65) 0.14 0.25 
Diabetes mellitus 86 13 (15) 7 (13) 6 (19) 0.61 0.68 
Coronary heart 
disease 
85 7 (8) 4 (7) 3 (10) >0.99 >0.99 
Chronic obstructive 
lung disease 
86 9 (10) 7 (13) 2 (6) 0.54 0.67 
Computed Tomography#  
Consolidation 78 46 (59) 30 (59) 16 (59) >0.99 >0.99 
Ground glass opacity 78 72 (92) 47 (92) 25 (93) >0.99 >0.99 
Bilateral infiltration 78 70 (90) 44 (86) 26 (96) 0.32 0.47 
Scores§  
qSOFA score 33 71 30 (42) 13 (28) 17 (68) 0.0028 0.0073 
CURB-65 score34 ≥ 1 47 22 (47) 11 (41) 11 (55) 0.50 0.67 
MuLBSTA score35 68 11 (0 - 15) 9 (0 - 15) 11 (5 - 15) 0.090 0.17 
Laboratory 
parameters # 
Evaluable  Median 
(range) 
Mechanical ventilation  p-value  q-value  
No (n = 57) Yes (n = 32) 
Lymphocyte count 
(G/l)  




0.94 (0.20 – 
2.84) 
0.60 0.68 
CRP (mg/l) 89 36 (0 - 369) 20 (0 - 315) 93 (16 - 369) 1.9·10-7 2.6·10-6 
Bilirubin (mg/dl) 84 0.5 (0.2 – 1.9) 0.5 (0.2 – 
1.2) 
0.6 (0.2 – 1.9) 0.19 0.32 
WBC (G/l) 89 5.86 (0.15 – 
308) 
5 (1.92 – 
12.4) 
7.26 (0.15 - 
308) 
0.0024 0.0073 
LDH (U/l) 88 311 (153 - 
1121) 
278 (153 - 
619) 
462 (240 - 
1121) 
1.5·10-6 0.000010 
PCT (ng/ml) 87 0 (0 - 5) 0 (0 – 0.6) 0.2 (0 - 5) 8.7·10-7 8.1·10-6 
IL-6 (pg/ml) 86 34 (0 - 430) 23.2 (0 - 
209) 





89 194 (0.12 - 
450) 
194 (0.27 - 
383) 
202 (0.12 - 
450) 
0.55 0.67 
Troponin T (ng/ml) 78 0 (0 – 0.178) 0 (0 – 
0.143) 
0 (0 – 0.178) 0.0001
0 
0.00047 
Creatinine (mg/dl) 89 0.9 (0.4 – 7) 0.9 (0.4 – 
5.6) 
1.1 (0.8 – 7) 5.2·10-6 0.000029 
D-Dimer 76 0.7 (0 – 35.2) 0.6 (0 – 35) 0.9 (0 – 35.2) 0.0079 0.018 
Ferritin (ng/ml) 79 703 (30 - 
3577) 
545 (30 - 
2578) 





* respiratory rate and heart rate and BMI (Body mass index) were measured at admission; 450 
existing comorbidities were evaluated by patient history at admission; # CT-scans and 451 
laboratory parameters at admission; § scores were calculated at admission. CRP = C-452 
Reactive Protein; WBC= White blood cell count; LDH = Lactate Dehydrogenase; PCT = 453 
Procalcitonin; IL6 = Interleukin-6; qSOFA score = predicts mortality in sepsis, CURB-65 454 
score = predicts mortality in community-acquired pneumonia, MuLBSTA score = predicts 455 
mortality in patients with viral pneumonia; q-values represent the Benjamini-Hochberg 456 
adjusted p-values 457 
 458 
 459 
Table 2: p-values, AUC’s and optimal cutoffs in eva luation, validation and combined cohort  
 
CRP = C-Reactive Protein; WBC= White blood cell count; LDH = Lactate Dehydrogenase; PCT = Procalcitonin; IL6 = Interleukin-6; AUC = area 
under the curve; CI = confidence interval 
Variable 
Evaluation set Validation set Combined cohort 


















































































































































































Table 3: Contingency table for high-risk and low-ri sk groups as defined by IL-6 and 460 









  470 
Variable Value  
Mechanical ventilation  
p-value  
No Yes 
IL-6 at presentation 
≤35 19 3 
0.0030 
>35 11 16 
  
Maximal IL-6 
≤80 25 5 
0.00022 
>80 5 14 
  
CRP at presentation  
≤32.5 19 1 
0.00019 
>32.5 11 18 
  
Maximal CRP 
≤97 23 3 
0.00011 
>97 7 16 
Figure legends 471 
Figure 1: Consort Diagram: 472 
Consort Diagram. DNR/DNI: do-not-resuscitate and do-not-intubate order. 473 
 474 
Figure 2: IL-6 at presentation, maximal IL-6 levels  before mechanical ventilation and 475 
ROC-analysis of different parameters in the evaluat ion and validation cohort 476 
Box plots showing IL-6 levels at first assessment (A, B) and maximal IL-6 levels before 477 
mechanical ventilation (C, D) in the evaluation cohort and in the validation cohort; dashed 478 
lines represents the cutoff calculated from the evaluation cohort (IL-6 at initial assessment 479 
>35 pg/ml, maximal IL-6 >80 pg/ml). Mean ± SD is shown. Receiver operating characteristic 480 
(ROC) curve of maximal follow-up levels before mechanical ventilation in the evaluation (E) 481 
and validation cohorts (F).  482 
 483 
Figure 3: CRP levels at presentation and maximal CR P levels before mechanical 484 
ventilation 485 
Box plot showing CRP levels at first assessment (A, B) and maximal IL-6 levels before 486 
mechanical ventilation (C, D) in the evaluation cohort and in the validation cohort; dashed 487 
lines represents the cutoff calculated from the training cohort (CRP at assessment >32.5 488 
mg/l, maximal CRP>97 mg/l). Mean ± SD is shown.  489 
 490 
Figure 4: Cutoffs and predictive values of maximal IL-6 and CRP values in the 491 
combined cohort 492 
Box plots depicting the maximal values of IL-6 and CRP in the overall cohort (A, B); dashed 493 
line represents the validated cutoff; dotted line represents the calculated improved cutoff 494 
from all patients (applicable only for IL-6). Positive predictive value (PPV) and negative 495 
predictive value (NPV) as a function of different cutoffs is shown for IL-6 (C) and CRP (D) 496 
values (dotted line represents cutoff for perfect NPV; dashed line represents cutoff for perfect 497 
PPV) 498 
 499 
Figure 5: Time from exceeding the maximal cutoff va lue of IL-6 or CRP to intubation in 500 
the combined cohort 501 
Box plot depicting the time from exceeding the IL-6 (>65 ng/ml) and CRP (>97 mg/l) cutoff to 502 









Elevated levels of interleukin-6 and CRP predicts the need for mechanical ventilation 
in COVID-19 





Table E1: Evaluation Cohort 
Variable Evaluable Median (range) / 
n (%) 
Mechanical ventilation p-value q-value 
No (n = 27) Yes (n = 13) 
Baseline Characteristics *  
Age (years) 40 57 (19 - 81) 54 (19 - 80) 64 (45 - 81) 0.15 0.29 
Respiratory rate (/min) 34 18 (14 - 40) 18 (14 - 32) 23 (15 - 40) 0.066 0.14 
Heart rate (/min) 32 81 (54 - 112) 77 (54 - 111) 94 (80 - 112) 0.0069 0.022 
BMI 30 25.9 (19.0 – 
45.7) 
23.7 (19.0 – 
34.7) 
30.5 (24.8 – 
45.7) 
0.0030 0.014 
Male gender 40 29 (72) 16 (59) 13 (100) 0.020 0.051 
Any comorbidities 39 32 (82) 20 (77) 12 (92) 0.46 0.81 
Hypertension 38 19 (50) 10 (40) 9 (69) 0.17 0.32 
Diabetes mellitus 38 3 (8) 1 (4) 2 (15) 0.55 0.82 
Coronary heart disease 36 3 (8) 3 (12) 0 (0) 0.52 0.82 
Chronic obstructive lung 
disease 
37 3 (8) 2 (8) 1 (8) >0.99 >0.99 
Computed Tomography#  
Consolidation 36 21 (58) 14 (61) 7 (54) 0.95 >0.99 
Ground glass opacity 36 31 (86) 20 (87) 11 (85) >0.99 >0.99 
Bilateral infiltration 36 33 (92) 21 (91) 12 (92) >0.99 >0.99 
Scores§  
qSOFA score 1 32 12 (37) 7 (32) 5 (50) 0.55 0.82 
CURB-65 score2 ≥ 1 24 7 (29) 5 (31) 2 (25) >0.99 >0.99 
MuLBSTA score3 29 9 (4 - 15) 9 (4 - 13) 7 (5 - 15) 0.89 >0.99 
Laboratory 
parameters# 
Evaluable Median (range) Mechanical ventilation p-value q-value 
No (n = 27) Yes (n = 13) 
Lymphocyte count G/l 31 0.99 (0.45 – 
2.50) 
0.99 (0.45 – 
1.80) 
0.95 (0.57 – 
2.50) 
0.92 >0.99 
CRP (mg/l) 40 28 (0 – 315) 17 (0 – 315) 77 (16 – 
171) 
0.0031 0.014 
Bilirubin (mg/dl) 37 0.5 (0.2 – 1.9) 0.5 (0.2 – 
1.2) 
0.5 (0.4 – 
1.9) 
0.78 >0.99 
WBC (G/l) 40 5.04 (2.12 - 308) 4.67 (2.12 – 
10.8) 
7.38 (4.67 - 
308) 
0.0028 0.014 
LDH (U/l) 39 285 (153 - 1078) 258 (153 - 
619) 
381 (252 - 
1078) 
0.00062 0.0058 
PCT (ng/ml) 38 0 (0 - 5) 0 (0 – 0.6) 0.1 (0 - 5) 0.0043 0.017 
IL-6 (pg/ml) 37 27.1 (0 - 430) 19.6 (0 – 
76.5) 
121 (19.2 - 
430) 
0.000012 0.00034 
Thrombocyte count (G/l) 40 161 (0.12 - 440) 162 (0.27 - 
334) 
160 (0.12 - 
440) 
0.74 >0.99 
Troponin T (ng/ml) 34 0 (0 – 0.032) 0 (0 – 0.022) 0 (0 – 0.032) 0.0053 0.019 
Creatinine (mg/dl) 40 0.9 (0.4 – 2.1) 0.9 (0.4 – 
1.3) 
1.0 (0.9 – 
2.1) 
0.00051 0.0058 
D-Dimer 31 0.7 (0 – 2.9) 0.6 (0 – 2.2) 1.1 (0.6 – 
2.9) 
0.019 0.051 
Ferritin (ng/ml) 31 626 (46 - 2153) 553 (46 - 
1748) 




* respiratory rate and heart rate and BMI (Body mass index) were measured at admission; 
existing comorbidities were evaluated by patient history at admission; # CT-scans and 
laboratory parameters at admission; § scores were calculated at admission. CRP = C-
Reactive Protein; WBC= White blood cell count; LDH = Lactate Dehydrogenase; PCT = 
Procalcitonin; IL6 = Interleukin-6; qSOFA score = predicts mortality in sepsis, CURB-65 
score = predicts mortality in community-acquired pneumonia, MuLBSTA score = predicts 
mortality in patients with viral pneumonia; q-values represent the Benjamini-Hochberg 
adjusted p-values 
  
Table E2: Validation cohort 
Variable Evaluable Median (range) / 
n (%) 
Mechanical ventilation p-value q-value 
No (n = 30) Yes (n = 19) 
Baseline Characteristics *  
Age (years) 49 64 (18 - 84) 61 (18 - 84) 65 (46 - 81) 0.18 0.31 
Respiratory rate (/min) 34 18 (11 - 40) 17 (13 - 39) 26 (11 – 40) 0.027 0.083 
Heart rate (/min) 34 90 (64 - 130) 94 (74 - 130) 86 (64 - 107) 0.033 0.091 
BMI 41 27.5 (18.1 – 
36.2) 
27.6 (18.1 – 
36.2) 
27.0 (18.4 – 
34.7) 
0.58 0.71 
Male gender 49 33 (67) 17 (57) 16 (84) 0.091 0.21 
Any comorbidities 48 38 (79) 23 (77) 15 (83) 0.85 0.96 
Hypertension 48 26 (54) 15 (50) 11 (61) 0.65 0.76 
Diabetes mellitus 48 10 (21) 6 (20) 4 (22) >0.99 >0.99 
Coronary heart disease 49 4 (8) 1 (3) 3 (16) 0.31 0.46 
Chronic obstructive lung 
disease 
49 6 (12) 5 (17) 1 (5) 0.46 0.61 
Computed Tomography#  
Consolidation 42 25 (59) 16 (57) 9 (64) >0.99 0.98 
Ground glass opacity 42 41 (98) 27 (96) 14 (100) >0.99 >0.99 
Bilateral infiltration 42 37 (88) 23 (82) 14 (100) 0.24 0.37 
Scores§  
qSOFA score 1 39 18 (46) 6 (25) 12 (80) 0.0025 0.010 
CURB-65 score2 ≥ 1 23 15 (65) 6 (55) 9 (75) 0.55 0.71 
MuLBSTA score3 39 11 (0 - 15) 10 (0 - 15) 13 (9 - 15) 0.038 0.096 
Laboratory 
parameters# 
Evaluable Median (range) Mechanical ventilation p-value q-value 
No (n = 30) Yes (n = 19) 
Lymphocyte count G/l 36 0.80 (0.20 – 
2.84) 
0.73 (0.31 – 
2.36) 
0.94 (0.20 – 
2.84) 
0.43 0.60 
CRP (mg/l) 49 42 (1 – 369) 22 (1 – 163) 134 (31 – 
369) 
0.000032 0.00068 
Bilirubin (mg/dl) 47 0.5 (0.2 – 1.2) 0.4 (0.2 – 
1.2) 
0.6 (0.2 – 
1.1) 
0.16 0.30 
WBC (G/l) 49 6.0 (0.15 – 25.8) 5.79 (1.92 – 
12.4) 
7.22 (0.15 – 
25.8) 
0.13 0.26 
LDH (U/l) 49 336 (181 - 1121) 278 (181 - 
502) 
474 (240 - 
1121) 
0.00032 0.0022 
PCT (ng/ml) 49 0 (0 – 2.3) 0 (0 – 0.3) 0.2 (0 – 2.3) 0.000073 0.00068 
IL6 (pg/ml) 49 42.7 (0 - 272) 23.7 (0 - 
209) 
83.5 (14.2 - 
272) 
0.000072 0.00068 
Thrombocyte count (G/l) 49 216 (93 - 450) 212 (112 - 
383) 
220 (93 - 
450) 
0.23 0.37 
Troponin T (ng/ml) 44 0 (0 – 0.178) 0 (0 – 0.143) 0.022 (0 – 
0.178) 
0.0078 0.027 
Creatinine (mg/dl) 49 0.9 (0.5 – 7.0) 0.9 (0.5 – 
5.6) 
1.1 (0.8 – 
7.0) 
0.0023 0.010 
D-Dimer 45 0.8 (0 – 35.2) 0.6 (0 - 35) 0.9 (0 – 35.2) 0.11 0.24 
Ferritin (ng/ml) 48 789 (30 - 3577) 508 (30 - 
2578) 




* respiratory rate and heart rate and BMI (Body mass index) were measured at admission; 
existing comorbidities were evaluated by patient history at admission; # CT-scans and 
laboratory parameters at admission; § scores were calculated at admission. CRP = C-
Reactive Protein; WBC= White blood cell count; LDH = Lactate Dehydrogenase; PCT = 
Procalcitonin; IL6 = Interleukin-6; qSOFA score = predicts mortality in sepsis, CURB-65 
score = predicts mortality in community-acquired pneumonia, MuLBSTA score = predicts 
mortality in patients with viral pneumonia; q-values represent the Benjamini-Hochberg 
adjusted p-values 
  
Supplementary Table E3: Comparison Evaluation and Validation cohort 
Variable Cohort p-value 
Evaluation (n = 40) Validation (n = 49) 
Baseline Characteristics *    
Age (years) 57 (19 - 81) 64 (18 - 84) 0.15 
Respiratory rate (/min) 18 (14 - 40) 18 (11 - 40) 0.76 
Heart rate (/min) 81 (54 - 112) 90 (64 - 130) 0.017 
BMI 25.9 (19.0 – 45.7) 27.5 (18.1 – 36.2) 0.18 
Male gender 29 (72) 33 (67) 0.77 
Any comorbidities 32 (82) 38 (79) 0.95 
Hypertension 19 (50) 26 (54) 0.87 
Diabetes mellitus 3 (8) 10 (21) 0.17 
Coronary heart disease 3 (8) 4 (8) >0.99 
Chronic obstructive lung 
disease 
3 (8) 6 (12) 0.79 
Computed Tomography#    
Consolidation 21 (58) 25 (60) >0.99 
Ground glass opacity 31 (86) 41 (98) 0.14 
Bilateral infiltration 33 (92) 37 (88) 0.89 
Scores§    
qSOFA score 1 12 (37) 18 (46) 0.62 
CURB-65 score2 ≥ 1 7 (29) 15 (65) 0.029 
MuLBSTA score3 9 (4 - 15) 11 (0 - 15) 0.13 
Laboratory parameters# Cohort p-value 
Evaluation (n = 40) Validation (n = 49) 
Lymphocyte count G/l 0.99 (0.45 – 2.5) 0.8 (0.2 – 2.84) 0.27 
CRP (mg/l) 28 (0 – 315) 42 (1 – 369) 0.10 
Bilirubin (mg/dl) 0.5 (0.2 – 1.9) 0.5 (0.2 – 1.2) 0.71 
WBC (G/l) 5.04 (2.12 - 308) 6 (0.15 – 25.8) 0.47 
LDH (U/l) 285 (153 - 1078) 336 (181 - 1121) 0.18 
PCT (ng/ml) 0 (0 – 5) 0 (0 – 2.3) 0.32 
IL-6 (pg/ml) 27.1 (0 - 430) 42.7 (0 - 272) 0.34 
Thrombocyte count (G/l) 161 (0.12 - 440) 216 (93 - 450) 0.0084 
Troponin T (ng/ml) 0 (0 – 0.032) 0 (0 – 0.178) 0.016 
Creatinine (mg/dl) 0.9 (0.4 – 2.1) 0.9 (0.5 – 7.0) 0.82 
D-Dimer 0.7 (0 – 2.9) 0.8 (0 – 35.2) 0.57 
Ferritin (ng/ml) 626 (46 - 2153) 789 (30 - 3577) 0.20 
 
* respiratory rate and heart rate and BMI (Body mass index) were measured at admission; 
existing comorbidities were evaluated by patient history at admission; # CT-scans and 
laboratory parameters at admission; § scores were calculated at admission. CRP = C-
Reactive Protein; WBC= White blood cell count; LDH = Lactate Dehydrogenase; PCT = 
Procalcitonin; IL6 = Interleukin-6; qSOFA score = predicts mortality in sepsis, CURB-65 
score = predicts mortality in community-acquired pneumonia, MuLBSTA score = predicts 
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